Shannon Life Sciences

Our deep resources and industry knowledge make us the ideal partner to scientists and entrepreneurs worldwide. Pivotal Life Sciences is an investment platform that specializes in providing capital to innovative companies developing therapeutic products and technologies to address major unmet medical needs. The name “Pivotal” synthesizes our investment approach with the role we strive to play in the companies we invest in. Our strategy is to invest in companies of all stages, with a primary focused on “high impact” therapeutics – solutions that address growing unmet medical needs and with near-curative or otherwise transformative disease management potential. We look for companies at the cusp of their greatest de-risking value inflection point and strive to play a key role in company building alongside management.

Harmonix invests in technological breakthroughs that will help create a future for a healthy, operational, and peaceful civilization. The fund focuses on exceptional entrepreneurs and innovative healthcare, life sciences, and deep tech companies. Harmonix is a multi-disciplinary team comprising scientists, researchers, operators, entrepreneurs, and industry experts with over 70 years of cumulative experience. Our diverse team provides founders with deep technical, operating, industry, and advisory expertise to accelerate and commercialize the next generation of technological advances. Harmonix accelerates scientific discoveries to advance human health and technology. We invest in companies that have functional solutions to real world problems. The Harmonix Process We deploy an evidence-based due diligence framework in assessing companies. Research: We identify opportunities ripe for innovation and examine areas where current standards of R&D, care, treatment, or workflow processes are inadequate. We find companies with functional solutions to problems that can create real value for stakeholders. Invest: We assess not only the technical dimensions of a venture, including supporting proof-of-concept data but also founder-fund fit. Our team looks for founders with emotional intelligence and demonstrated capacity for leadership and integrity. Accelerate: We support founders in all realms of the entrepreneurial process, including technical, operational, and business development support. We offer access to advisors who provide a level of expertise that is unavailable to many early-stage scientific companies.

Cambrian Biopharma, a multi-asset longevity biotech, is building the medicines that will redefine healthcare in the 21st century – therapeutics to lengthen healthspan, the period of life spent in good health. By partnering with leading academic institutions and biotech entrepreneurs all over the world, we are advancing a diversified pipeline of novel therapeutics, each targeting a biological driver of aging. Our approach is to develop interventions that treat specific diseases first, then deploy them as preventative medicines to improve overall quality of life as we age. Cambrian is a Distributed Development Company (or DisCo) which combines the advantages of a venture capital firm and a big pharmaceutical company, with the nimbleness of a biotech startup. Cambrian’s sourcing and development engine allows us to identify promising science, deploy capital and teams of drug development experts, and provide stewardship to advance new medicines. By leveraging established expertise and repeatable functional models, we achieve vast efficiencies in execution speed and resource utilization. To date, we have 14 novel therapeutics in development, and having closed a Series C financing round in October 2021 which raised $100 million, we plan to expand the number of programs. Further, we expect to initiate clinical trials for three programs in the next 18 months.

When we founded the firm in 2007, our imaginations were on fire with the possibility of translating scientific discoveries to breakthrough medicines. Could we finally find cures for cancer? Would we be able to diagnose diseases before they even appear? How far could we go in restoring hope and quality of life to patients with incurable conditions? We dared to believe that nothing was impossible. To achieve what hadn’t been done before, we created a process that hadn’t been done before. By starting with big ideas and fostering collaboration among brilliant people with expertise in science, medicine, business and strategy, we set out to do more than fund startups – we aim to build sustainable, innovative companies that can transform the lives of patients. Discover Our Discovery effort is a collaborative and iterative process. We look for emerging fields of science and medicine where the time is right for us to bring transformative change to areas of unmet medical need. Working with leading scientific founders and expert advisors, we then develop a clear vision and strategy for a company with the patient front and center. With 12 years and over 50 companies worth of experience, we have created an industry-leading and differentiated approach to bring breakthrough science to patients. Launch Once a company concept has been refined and optimized through our Discovery process, we Launch the company with the necessary financial, technical and human resources to enable it to reach milestones critical for its growth and success. We become active members of the company’s leadership team, serving in interim roles to ensure the execution of the company’s R&D strategy, and to build a world-class team that shares the company’s scientific vision. Importantly, we work to establish a dynamic and innovative culture at launch where the growing team has a unified passion and commitment to make a difference in the lives of patients. Build Next, we Build on that foundation. We transition out of our interim roles and establish experienced and motivated management teams. As board members and domain experts, we work with these teams for as long as is needed to relentlessly execute on the strategy, bringing whatever resources are required from within the firm to deliver on our commitment to patients. An important element is the work we do to cultivate future partnerships and drive value creating transactions. Our companies also have access to our Beyond Great learning community, which provides peer-to-peer networking for leaders across the portfolio as well as tools and resources focused on shared elements of building successful and sustainable companies. Transform Our companies are now bringing products to patients – Transforming their lives, and the lives of their families. Third Rock portfolio companies have now launched 16 products. It is this that we are most proud of, as it means we are delivering on our mission of creating great companies that discover and develop products that make a difference for the patients we serve. Mission & Core Values Third Rock's mission is to be the preferred partner for entrepreneurs, investors, employees and industry to build great companies that discover and develop products that make a difference for the patients we serve. Integrity: always do the right thing Attitude: nothing is impossible Patients: making a difference through breakthroughs in medicine Partners: make them raving fans Organization: great people, great culture, great accomplishments Entrepreneurs: passionately innovate, found, build, have fun

InnoCom makes investments into worthy Life Science companies, providing: Investment opportunities in cutting edge technologies Access to early commercialization for life Science innovators Capital of $3 to 15 Million USD initial tranche for a company to complete its R&D, Preclinical & Phase I Trials; additional funding to complete Phase II Trials to take products to Licensing Industry networking to access revenue at 2-3 years following pre-clinical trials Providing revenue and/or takeout at 7 years end of clinical trials Business Counsel and advice to the company management team Corporate Officer participation, setting up strong Systems, Procedures, and Protocols Board of Directors Membership, building strong Corporate Governance Life Science Expertise, providing commercialization at the end of Preclinical and/or Clinical I & II Trials at 2-3 years Licensing Upfront Fees at 3 years, Revenue and/or Takeout at end of Clinical Trials at 7 years Enhancing the delivery of health solutions to the patients who need them

We invest in groundbreaking medicines across disease area, financing stage, and geography, with a focus on programs in, or about to enter, human trials. We are curious, rigorous, collaborative, and passionate about our work; we are also long-term investors in our team.